Private Equity

Other Private Equity/Strategic Investments

PharmEasy in talks to raise $200-M at 25% lower valuation

Mint  

Indian drug and medical services startup PharmEasy is in talks with investors to raise USD 200 million, but at a valuation that could be 15% or 25% lower than last year's USD 5.1 Billion.

From the Venture Intelligence PE-VC Deal Database: Between January 2016 and October 2021, Pharmeasy had raised over USD 1780 M from Neuberger Berman, ADQ, Trifecta Capital, Steadview Capital , IIFL VC, OrbiMed, Amansa Capital, Think Investments, B Capital Group, Prosus Ventures, Orios VP, TPG Growth, Kotak Investment Advisors, Temasek, Tiger Global, JM Financial, Lightrock India, TPG Capital, CDPQ, Eight Roads Ventures, Fundamentum, Bessemer, KB Investment, InnoVen Capital, Astarc Ventures and Aarin Capital. (Subscribers to the database can login to view the valuation, deal structuring and other transaction details.)